A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors

PURPOSE: Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor, which selectively inhibits VEGFR2/3, FGFR1-4, PDGFR α/β, c-kit, and Ret. It shows antitumor effect in patients with advanced refractory solid tumors. The detailed absorption, metabolism, and excretion pathways of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yiqian, Liu, Lianke, Liu, Lingxiang, Wang, Tongshan, Guo, Lian, Wang, Yixiang, Gao, Zhengzhen, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188728/
https://www.ncbi.nlm.nih.gov/pubmed/32266457
http://dx.doi.org/10.1007/s00280-020-04062-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188728/
https://www.ncbi.nlm.nih.gov/pubmed/32266457
http://dx.doi.org/10.1007/s00280-020-04062-8

Ejemplares similares